

Asia-Pacific Histocompatibility And Immunogenetics Association Annual Scientific Meeting (APHIA 2025)

5-7th February 2025

Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society 12th Floor, Bhumisiri Mangkhalanusorn Building

Final Schedule

Tuesday Feb 4th, 2025 Pre-congress Workshop at the Thai Red Cross Society (Thermo Fisher)

MagSort workshop (Pre-Registration required)
Break
Welcome
Pre-Transplant Session:
Investigating complex antibody patterns using Single Antigen with MagSort
Case Study Presentations
Understanding Epitopes and making better decisions with HLA MatchMaker
Lunch
Post-Transplant Session: Non-invasive biomarker monitoring using Cell Free DNA
Case Study Presentations
Break

Wednesday Feb 5th, 2025 (Day 1)

7.00 - 8.30Registration Open8.15 - 8.30Opening Ceremony



Program supported by Thailand Hub of Talents in Cancer Immunotherapy, TTCI)

8.30 - 10.00	Plenary Session 1: Cellular Immunotherapy I
	 Role of HSCT vs CAR T cells in Hematologic Malignancy
	O Assoc. Prof. Kitsada Wudhikarn, Division of Hematology, Faculty of
	Medicine, Chulalongkorn University, Thailand
	Challenges in delivering cellular therapies for transplant recipients and cancer
	patients
	O Prof.Rajiv Khanna, Co-Director, Queensland Immunology Research
	Centre; Distinguished Scientist, Tumour Immunology Laboratory,
	QIMR Berghofer Medical Research Institute, Australia
	 mRNA-based T cell engineering for treatment of virus-related cancer and virus
	infection
	O Prof.Antonio Bertoletti, Duke-NUS Graduate Medical School,
	Singapore
10.00 - 10.30	Coffee Break with Poster Session I
10.30 – 12.00	Plenary Session 2: Cellular Immunotherapy II
	Clinical Application of Mesenchymal Stem Cells: Current Trends and Future
	Directions
	O Prof.Jacques Galipeau,
	Associate Dean for Therapeutics Development

University of Wisconsin School of Medicine and Public Health, University of Wisconsin in Madison, USA

- T cell receptors and MHC diversity in risk, prognosis, and therapy for gliomas
 - Asst. Prof.Gary Kohanbash, Director, PNIO Laboratory, Faculty of the Department of Neurological Surgery at UPMC Children's Hospital of Pittsburgh, USA
- Novel pans solid tumor CAR T cells and first in human trial in DIPG
 - Assoc. Prof.Supannikar Tawinwung, Cellular Immunotherapy
 Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn
 University; Facility Director, Cell and Gene Therapy Manufacturing
 Center, King Chulalongkorn Memorial Hospital, Thailand

12.00 – 13.00	Lunch Break		
13.00 – 13.30	Sponsor Sessior	n I (Care Dx)	
	Advance	ements in HLA loci and Permissive vs. Non-permissive Mismatches	
13.30 - 14.00	Sponsor Sessior	n II (Gen Dx)	
	 Revolut 	ionizing Rapid High Resolution HLA Typing with NGS-Turbo® and	
	NGS-Pr	ronto® using Oxford Nanopore Technologies sequencing	
14.00 - 14.30	Short Oral Prese	ntation I	
	● HLA-E1	triggers carcinogenesis in cervix	
	0	Prof. Ritu Aggarwal, Department of Immunopathology, Postgraduate	
		Institute of Medical Education and Research, Chandigarh, India	
	• Workup	and validation of high throughput method for HLA high resolution	
	allelic g	enotyping, ABO typing and CMV IgG status	
	0	Assoc. Prof. Abha Chopra, Murdoch University, Australia	
	 Anti-TR 	OP2 CAR-T cells secreting anti-NECTIN2 scFv effectively kill high	
	TROP2	and NECTIN2 breast cancer cells	
	0	Dr. Suyanee Thongchot, Mahidol University, Thailand	
14.30 – 16.00	Coffee Break wit	h Poster Session I	
14.00 – 16.30	Concurrent Work	<pre>kshop I (Hillgene/BKGI): Room 1201</pre>	
	14.30 – 15.00	Navigating Regulatory CMC Challenges in Advanced Therapies	

	15.00 – 15.30	International Perspective for Research and Development Strategies
		of Cell Drugs
	15.30 – 16.00	BCMA CAR-T on Clinical Application and Technological Development
		Trends
	16.00 - 16.30	Round table discussion and Networking: The Present and Future of
		Cell Therapeutics in Diversity Disease Treatment Applications
18.00 - 21.00	Welcome Recep	tion
	(Mandarin Hotel,	Managed by Center Point)

Thursday Feb 6th, 2025 (Day 2)

8.30 – 10.00 Plenary Session 3: Haematopoietic Stem Cell Transplantation

- HSCT: An update
 - Dr.Dianne De Santis, PhD, FFSc (RCPA) Clinical Scientist Department of Clinical Immunology, PathWest, Fiona Stanley Hospital Adjunct Senior Teaching Fellow, University of Western Australia
- Saving Lives Across Borders: The Asia-Pacific Unrelated Stem Cell Donor Registry Experience
 - Pawinee Kupatawintu, National Blood Center, the Thai Red Cross Society, Thailand
 - Prof.Ram Mohan Jaiswal, Mahatma Gandhi Medical College & Hospital), India

0	Garth Healey	Australian Bon	e Marrow Donoi	Registry, Australia
---	--------------	----------------	----------------	---------------------

10.00 – 10.30 Coffee Break with Poster Session II

10.30 – 12.00 Plenary Session 4:HLA Genomics and Clinical Relevance

- HLA in Diseases Susceptibility and Personalized Medicine
 - Prof.Katsushi Tokunaga, Director, Genome Medical Science Project, Research Institute, National Center for Global Health and Medicine (NCGM); Director, Central Biobank, National Center Biobank Network (NCBN)), Japan
- Clinical implementation of HLA long-read sequencing
 - A/Prof.Pajaree Lilitkarntakul, Center of Excellence in Clinical
 Pharmacokinetics and Pharmacogenomics, Department of
 Pharmacology, Faculty of Medicine, Chulalongkorn University),
 Thailand
- HLA Typing and Beyond with Nanopore Sequencing
 - Dr.Thidathip Wongsurawat, Head Division of Medical Bioinformatics,
 Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
- Beyond Traditional HLA Typing: NGS and HLA Imputation for Comprehensive Analysis of HLA Alleles in Thai SLE Patients
 - Dr.Charles Khor Seik-Soon, Singapore Centre for Environmental Life
 Sciences Engineering, Nanyang Technological University, Singapore
- 12.00 13.00 Lunch Break
- 13.00 13.30Sponsor Session III (Thermo Fisher): Development and Validation of a High-Throughput
Method for HLA High-Resolution Allelic Genotyping, ABO Typing, and CMV IgG Status
Detection
- 13.30 14.00 Sponsor Session IV (TBG): HLA Typing using Nanopore with Automation
- 14.00 14.30 Short Oral Session II
 - HLA Diversity & DSA in Australian Donors
 - O Mr. Steven Hiho, Australian Redcross Lifeblood, Australia
 - Lnc RNAs may predict allograft rejection
 - O Dr. UMA KANGA, All India Institute of Medical Sciences, India
 - Characterisation of the Human Blood Group using third-generation sequencing

	0	Dr. Fredrick Mobegi, Department of Clinical Immunology, PathWest	
		Laboratory Medicine WA, Fiona Stanley Hospital Network, Australia	
14.30 - 16.00	Coffee Break wi	th Poster Session II	
14.00 - 16.30	Concurrent Workshop II (Werfen): Room 1201		
	• Werfen	HLA Innovation Station	
	14.00 - 14.10	Welcome to the Delegates	
	14.20 - 14.40	Transplant Innovation & what's in the Pipeline for the future	
	14.40 – 15.20	It's not just a Software – Match X	
	15.20 – 16.00	NGS Solutions – The new kid on the block	
	16.00 – 16.20	The Lesser–known Devil – Non HLA	
18.00 - 21.00	Gala Dinner (Co	ouncilor and Speaker Plus Guest with ticket)	

Friday Feb 7th, 2025 (Day 3)

8.30 – 10.00	Plenary Session 5:Solid Organ Transplantation I		
		entation of Virtual Crossmatching in Australia: the laboratory	
	experie	nce	
	0	Fiona Hudson, Senior Scientist at VTIS, Melbourne, Australia	
	• Determi	ining compatibility in Solid Organ Transplantation – Challenges and	
	Opportu	unities	
	0	Rhonda Holdsworth	
		HLA Specialist and Clinical Scientist	
		Specialist Advisor, Transplantation and Immunogenetics Services	
		Pathology and Clinical Governance Division, Australian Red Cross	
		Lifeblood, Australia	
	• Non-HL	A antibodies in solid organ transplant	
	0	Dr Lucy Sullivan, Scientific Director at Australian Red Cross LifeBlood,	
		Australia	
10.00 – 10.30	Coffee Break wit	h Poster Session III	
10.30 - 12.00	Interactive Session		
		udies for Complex Patients	
	• Case St	udies for Complex Patients	
	• Case St	udies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond,	
	• Case St	tudies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of	
	 Case St O 	tudies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand	
	 Case St O 	tudies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine,	
	• Case St O O	audies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand	
	• Case St O O	audies for Complex Patients Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand Dr.Mary Diviney, Senior Clinical Scientist / Manager, Victorian	
	• Case St O O	Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand Dr.Mary Diviney, Senior Clinical Scientist / Manager, Victorian Transplantation and Immunogenetics Service (VTIS), Australian Red	
	 Case St O O 	Assoc. Prof.Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand Dr.Mary Diviney, Senior Clinical Scientist / Manager, Victorian Transplantation and Immunogenetics Service (VTIS), Australian Red Cross Lifeblood, Australia	

13.00 - 13.30	Special Lecture by the ASHI President
	 Expanding Access to Transplantation: Utilization of A2 Kidneys for O and B
	Recipient
	O Dr. Cathi Murphey, Director, Histocompatibility and Immunogenetics
	Laboratory, Southwest Immunodiagnostics, Inc. San Antonio, USA
13.30 - 14.00	Sponsor Session V (Thermo Fisher): Improving the Efficiency and Reliability of Post-
	Transplantation Monitoring and Prognosis with Donor-Derived Cell-Free DNA (dd-
	cfDNA)
14.00 – 14.30	Short Oral Session III
	 Identification of Human Leukocyte Antigen mismatches from an in-situ renal
	allograft biopsy in a patient re-entering the kidney transplant waitlist
	O Mrs. Alicia Crisafio, PathWest Clinical Immunology, Australia
	Discrepancy in Deceased Donor Typing
	O Mrs. Arishma Lata, New Zealand Blood Services, New Zwaland
	 Imlifidase desensitisation: lab outlooks
	O Dr. Sarah Lloyd, Lifeblood, Australia
14.30 – 15.00	Coffee Break with Poster Session III
15.00 - 16.00	Plenary Session 6:Solid Organ Transplantation II
	 Management of Highly sensitized kidney transplant recipients
	O Professor Jaeseok Yang, Division of Nephrology, Department of
	Internal Medicine, Yonsei University College of Medicine, Severance
	Hospital; Laboratory of Transplantation Immunology, Yonsei University
	Severance Hospital, Korea
	O Professor Yingyos Avihingsanon, Division of Nephrology, Department
	of Internal Medicine, Faculty of Medicine, Chulalongkorn University,
	Thailand
16.00 – 16.15	Concluding Remark and Closing